- Home
- PNR vs MRNA Comparison
PNR vs MRNA Comparison
Compare PNR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNR
- MRNA
- Stock Information
- Founded
- PNR 1966
- MRNA 2010
- Country
- PNR United Kingdom
- MRNA United States
- Employees
- PNR N/A
- MRNA N/A
- Industry
- PNR Industrial Machinery/Components
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PNR Industrials
- MRNA Health Care
- Exchange
- PNR Nasdaq
- MRNA Nasdaq
- Market Cap
- PNR 17.7B
- MRNA 16.5B
- IPO Year
- PNR N/A
- MRNA 2018
- Fundamental
- Price
- PNR $102.35
- MRNA $40.27
- Analyst Decision
- PNR Buy
- MRNA Hold
- Analyst Count
- PNR 16
- MRNA 19
- Target Price
- PNR $110.00
- MRNA $79.50
- AVG Volume (30 Days)
- PNR 1.1M
- MRNA 7.9M
- Earning Date
- PNR 01-28-2025
- MRNA 02-20-2025
- Dividend Yield
- PNR 0.90%
- MRNA N/A
- EPS Growth
- PNR 29.67
- MRNA N/A
- EPS
- PNR 4.00
- MRNA N/A
- Revenue
- PNR $4,094,500,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- PNR $0.48
- MRNA N/A
- Revenue Next Year
- PNR $4.12
- MRNA N/A
- P/E Ratio
- PNR $25.61
- MRNA N/A
- Revenue Growth
- PNR N/A
- MRNA N/A
- 52 Week Low
- PNR $68.08
- MRNA $35.80
- 52 Week High
- PNR $110.71
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- PNR 39.67
- MRNA 42.28
- Support Level
- PNR $100.45
- MRNA $38.52
- Resistance Level
- PNR $109.86
- MRNA $40.83
- Average True Range (ATR)
- PNR 1.89
- MRNA 2.59
- MACD
- PNR -1.02
- MRNA 0.12
- Stochastic Oscillator
- PNR 20.19
- MRNA 28.38
About PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Pentair's business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2023.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.